M Gupta

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling
    Guangzhen Hu
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 8:e67851. 2013
  2. pmc Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP
    Mamta Gupta
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 120:4400-6. 2012
  3. pmc Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy
    M Gupta
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:1356-64. 2012
  4. pmc Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation
    Mamta Gupta
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:2844-53. 2012
  5. pmc Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy
    T E Witzig
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, College of Medicine, Rochester, MN, USA
    Leukemia 28:147-54. 2014
  6. pmc A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
    T E Witzig
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    Leukemia 25:341-7. 2011

Detail Information

Publications6

  1. pmc A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling
    Guangzhen Hu
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 8:e67851. 2013
    ..These results indicate that missense mutations in STAT3 increase signaling through the JAK/STAT pathway. JAK2 inhibitors may be useful in the patient with this STAT3 mutation as well as those with pathway activation by other mechanisms. ..
  2. pmc Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP
    Mamta Gupta
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 120:4400-6. 2012
    ..05), G-CSF (P = .03), and TNF-α (P = .04). pSTAT3 IHC in DLBCL tumors has the potential to identify patients for STAT3 pathway-directed therapy; Myc IHC is a potential marker for inferior EFS in GCB patients...
  3. pmc Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy
    M Gupta
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:1356-64. 2012
    ..These studies provide the rationale for targeting STAT3-positive DLBCL tumors with HDAC inhibitors...
  4. pmc Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation
    Mamta Gupta
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:2844-53. 2012
    ..These results provide the rationale for testing JAK2 inhibitors in DLBCL patients, and indicate that serum IL-10 may be a biomarker to identify patients more likely to respond to JAK2-targeted therapy...
  5. pmc Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy
    T E Witzig
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, College of Medicine, Rochester, MN, USA
    Leukemia 28:147-54. 2014
    ..These studies have uncovered novel epigenetic mechanisms of PTPN6 suppression and suggest that PTPN6 may be a potential target of epigenetic therapy in DLBCL. ..
  6. pmc A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
    T E Witzig
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    Leukemia 25:341-7. 2011
    ..Everolimus has single-agent activity in relapsed/refractory aggressive NHL and provides proof-of-concept that targeting the mTOR pathway is clinically relevant...